


Novel coronavirus (SARS-CoV-2) vaccine (mRNA-1273)

Last program update: February 26, 2020

Modality	ID #	Program		Preclinical development	Phase 1	Phase 2	Phase 3 and commercial	Moderna rights
 Prophylactic vaccines	mRNA-1647	Cytomegalovirus (CMV) vaccine		[Progress bar: Preclinical development to Phase 2]				Worldwide
	mRNA-1893	Zika vaccine		[Progress bar: Preclinical development to Phase 1]				Worldwide <i>BARDA funded</i>
	mRNA-1172/ Merck V172	Respiratory syncytial virus (RSV) vaccine		[Progress bar: Preclinical development to Phase 1]				Merck to pay milestones and royalties
	mRNA-1177	Respiratory syncytial virus (RSV) vaccine		[Progress bar: Preclinical development to Phase 2]				
	mRNA-1653	hMPV/PV3 vaccine		Phase 1 (healthy volunteers)	Phase 1b (Age de-escalation) Seropositives			Worldwide
	mRNA-1345	Pediatric respiratory syncytial virus (RSV) vaccine <i>Future respiratory combo</i>		[Progress bar: Preclinical development to Phase 1]				Worldwide
	mRNA-1189	Epstein-Barr virus (EBV) vaccine		[Progress bar: Preclinical development to Phase 1]				Worldwide
	mRNA-1851	Influenza H7N9 vaccine		[Progress bar: Preclinical development to Phase 2]				Worldwide <i>Advancing subject to funding</i>
		mRNA-1273	Novel coronavirus (SARS-CoV-2) vaccine		[Progress bar: Preclinical development to Phase 1]			

mRNA vaccine (mRNA-1273) against SARS-CoV-2

- mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a prefusion stabilized form of the Spike (S) protein of the novel coronavirus, which was selected by Moderna in collaboration with investigators at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC), a part of the National Institutes of Health (NIH)
- First clinical batch for Phase 1, including fill and finishing of vials, was completed on February 7; Batch has been shipped to the NIAID for the Phase 1 study
- NIAID will conduct the Phase 1 clinical study under their IND



Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning potential development candidate applications, development candidate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates and forward-looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no mRNA drug has been approved in this new potential category of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.